Company Overview and News

16
SUPV / Grupo Supervielle S.A. null (Current Report of Foreign Issuer)

2018-09-14 sec.gov - 8
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 <
SUPV

10
Argentina New Plan - A Good First Step To Restore Lost Confidence

2018-09-05 seekingalpha - 1
"There are four kinds of countries: Developed Countries, Underdeveloped Countries, Japan —nobody knows why it grows— and Argentina —nobody knows why it doesn’t."
BMA SUPV BFR EEM

9
US Silica, Pitney Bowes Leapt into Wednesday’s 52-Week Low Club

2018-08-29 247wallst
August 29, 2018: Here are four stocks trading with heavy volume among 48 equities making new 52-week lows in Wednesday’s session. On the NYSE advancers led decliners by about 1.72 to 1, and on the Nasdaq, advancers led decliners by about 1.66 to 1.
PBI-B PBI LB SLCA SUPV PBOWP PBOWN

8
Mitek Systems, L Brands Plunge into Tuesday’s 52-Week Low Club

2018-08-28 247wallst
August 28, 2018: Here are four stocks trading with heavy volume among 42 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 1.16 to 1, and on the Nasdaq, advancers led decliners by about 1.05 to 1.
MITK LB SUPV

9
Dean Foods, Grupo Supervielle Dip into Monday’s 52-Week Low Club

2018-08-27 247wallst
August 27, 2018: Here are four stocks trading with heavy volume among 45 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 1.52 to 1, and on the Nasdaq, advancers led decliners by about 1.49 to 1.
AIMC ATAI SUPV DF

8
Applied Materials, L Brands Slip into Friday’s 52-Week Low Club

2018-08-24 247wallst
August 24, 2018: Here are four stocks trading with heavy volume among 58 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 2.13 to 1, and on the Nasdaq, advancers led decliners by about 1.82 to 1.
VIPS AMAT LB SUPV

11
SUPV / Grupo Supervielle S.A. null (Current Report of Foreign Issuer)

2018-08-24 sec.gov - 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 <
SUPV

11
Reality Hits Banks In Argentina

2018-08-23 seekingalpha - 2
Banks in Argentina are in Selling-Mode. The image of this brutal sector sell-off conveys its meaning more effectively than a description does.
BMA SUPV BFR

9
Solid EM Micro Despite Macro Angst

2018-07-20 seekingalpha
It has certainly been a challenging quarter, leading to conflicting and bifurcated views on the emerging markets asset class and contrasting macro angst with solid bottom-up metrics. Despite a fairly robust global economic and profit growth backdrop and reasonable valuations, investor sentiment is negative.
HTHT SSNLF CMLLF HDB 1317 500180 BC94 SMSN HDFCBANK SUPV SMSD

1001
Tracking Dan Loeb's Third Point Portfolio - Q1 2018 Update

2018-05-22 seekingalpha - 10
Dan Loeb's 13F portfolio value decreased from $13.86B to $13.32B this quarter. The number of positions decreased from 44 to 40.
PCG ATHTF STZ.B TWX CVS CRM SHW GGAL HON AABA AVGO DOW DOV MELI MAC AET MMM PBF GD TPRE WP KDMN UTX STZ BKI TWC BABA DVMT GOOGL MSFT APY MHK QCOM GRBK MGM FB DOV.WI LEN NXPI PAM PE NFLX PF GOOG BAX LEN.B MPC PAGS ADBE SPGI RSPP VMC MON ICE SWN HON EA WYNN LYB FTI.WI FMC ANTM DWDP BID NEXA BLK XRAY T SUPV DHR ANTX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to SUPV / Grupo Supervielle S.A. on message board site Silicon Investor.

Super Vision (SUPVA) Super Vision (SUPVA) Super Vision (SUPVA) SuperVision International Inc (SUPVU) SuperVision International Inc (SUPVU) SuperVision International Inc (SUPVU)
CUSIP: 40054A108